文献速递细菌感染、耐药与抗菌药物医院感染防控

通过β-内酰胺类降阶梯治疗预防脓毒症住院患者新发革兰阴性菌耐药:一项回顾性队列研究

Preventing New Gram-negative Resistance Through Beta-lactam De-escalation in Hospitalized Patients With Sepsis: A Retrospective Cohort Study.
PubMed 文献 · Clin Infect Dis · 2024-01-01

该回顾性队列纳入接受至少3天β-内酰胺类抗生素(前2天广谱,谱评分≥7)的脓毒症患者,分为降阶梯、不变和升级三组。主要结局为60天内临床培养分离出新的耐药革兰阴性菌。644/7742例(8.3%)发生新耐药,降阶梯组发生率最低(1.42/1000患者日),降阶梯相比不变组新耐药风险显著降低(HR 0.59,95%CI 0.48-0.73)。

要点

  • 脓毒症患者β-内酰胺类降阶梯相比不改变谱评分,新发革兰阴性菌耐药风险显著降低(HR 0.59)。
  • 降阶梯组耐药发生率最低,为1.42/1000患者日。
  • 该研究为迄今最大规模显示降阶梯预防抗菌药物耐药效用的研究。

核心结论

  • β-内酰胺类降阶梯治疗相比不改变谱评分,与脓毒症住院患者新发革兰阴性菌耐药风险降低相关。

研究设计与样本

  • 回顾性队列研究,纳入接受至少连续3天β-内酰胺类抗生素且前2天为广谱β-内酰胺类(谱评分≥7)的脓毒症住院患者。
  • 患者分为三组:β-内酰胺谱评分降阶梯组、谱评分不变组和谱评分升级组。
  • 主要结局为入组后60天内从临床培养中分离出新的耐药革兰阴性菌。
  • 采用Fine-Gray比例风险回归模型,将院内死亡作为竞争风险。

主要发现

  • 7742例患者中644例(8.3%)发生新发革兰阴性菌耐药。
  • 发生耐药的平均时间为23.7天,发病率为1.85/1000患者日(95%CI 1.71-2.00)。
  • 降阶梯组发病率最低,为1.42/1000患者日(95%CI 1.16-1.68)。
  • 与谱评分不变组相比,降阶梯组新发革兰阴性菌耐药风险显著降低(HR 0.59,95%CI 0.48-0.73)。

临床怎么用

  • 对于接受广谱β-内酰胺类治疗的脓毒症住院患者,可考虑β-内酰胺类降阶梯以降低新发革兰阴性菌耐药风险(基于回顾性队列研究结果,作者结论为降阶梯与耐药风险降低相关)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether antibiotic de-escalation reduces the risk of subsequent antibiotic resistance is uncertain. We sought to determine if beta-lactam (BL) antibiotic de-escalation is associated with decreased incidence of new Gram-negative resistance in hospitalized patients with sepsis. METHODS: In a retrospective cohort study, patients with sepsis who were treated with at least 3 consecutive days of BL antibiotics, the first 2 days of which were with a broad-spectrum BL agent defined as a spectrum score (SS) of ≥7 were enrolled. Patients were grouped into three categories: (1) de-escalation of beta-lactam spectrum score (BLSS), (2) no change in BLSS, or (3) escalation of BLSS. The primary outcome was the isolation of a new drug-resistant Gram-negative bacteria from a clinical culture within 60 days of cohort entry. Fine-Gray proportional hazards regression modeling while accounting for in-hospital death as a competing risk was performed. FINDINGS: Six hundred forty-four patients of 7742 (8.3%) patients developed new gram-negative resistance. The mean time to resistance was 23.7 days yielding an incidence rate of 1.85 (95% confidence interval [CI]: 1.71-2.00) per 1000 patient-days. The lowest incidence rate was observed in the de-escalated group 1.42 (95% CI: 1.16-1.68) per 1000 patient-days. Statistically significant reductions in the development of new gram-negative resistance were associated with BL de-escalation compared to no-change (hazards ratio (HR) 0.59 [95% CI: .48-.73]). CONCLUSIONS: De-escalation was associated with a decreased risk of new resistance development compared to no change. This represents the largest study to date showing the utility of de-escalation in the prevention of antimicrobial resistance.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Teshome BF, Park T, Arackal J, et al. Preventing New Gram-negative Resistance Through Beta-lactam De-escalation in Hospitalized Patients With Sepsis: A Retrospective Cohort Study. Clin Infect Dis. 2024. PMID: 38842541. doi:10.1093/cid/ciae253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。